Response to Letter to the Editor Re: Impact of the Prosigna assay on neoadjuvant treatment decision making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study [0.03%]
来信回复《Prosigna检测对HR阳性/HER2阴性早期乳腺癌患者新辅助治疗决策的影响——一项单中心前瞻性观察研究》
C Corti,S M Tolaney
C Corti
Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial [0.03%]
肿瘤浸润淋巴细胞与体重指数在早期HER2阳性乳腺癌中的相互作用：ShortHER试验的分析结果
M V Dieci,G Bisagni,S Bartolini et al.
M V Dieci et al.
Background: We demonstrated the prognostic role of tumor-infiltrating lymphocytes (TILs) in patients with early human epidermal growth factor receptor 2 (HER2)-positive breast cancer (eBC) enrolled in the ShortHER trial. ...
A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701) [0.03%]
BRAF V600E突变型转移性结直肠癌紫杉类耐药患者接受艾日布林治疗的多中心Ⅱ期临床研究（BRAVERY 研究）(EPOC1701)
T Masuishi,H Taniguchi,D Kotani et al.
T Masuishi et al.
Background: Based on the reported antitumor effects of microtubule inhibitors in xenograft models of BRAF V600E mutant colorectal cancer, this multicenter phase II study aimed to evaluate the efficacy and safety of eribul...
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer [0.03%]
泛亚版的ESMO临床实践指南：胰腺癌患者的诊断、治疗和随访
D Tai,T Conroy,J J X Lee et al.
D Tai et al.
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer, published in November 2023, were adapted in December 2024, according to previously ...
Understanding first-line treatment patterns and survival outcomes across sociodemographic groups of women with metastatic triple-negative breast cancer in the United States: a real-world study [0.03%]
理解美国不同社会人口统计学群体中转移性三阴乳腺癌女性的一线治疗模式和生存结果：一项真实世界研究
S M Tolaney,L Spring,Y G Abdou et al.
S M Tolaney et al.
Background: Triple-negative breast cancer (TNBC) has poor prognosis, and disproportionately affects young black women and BRCA1/2 mutation carriers. We describe sociodemographic differences in real-world treatment pattern...
Critical insights on real-life PD-L1 histopathological workflow and assessment in esophageal, esophagogastric junction, and gastric carcinoma in Italy [0.03%]
意大利食管、食管胃交界和胃癌中真实生活中的PD-L1病理学工作流程和评估的批判性见解
A Gambella,F Grillo,P Parente et al.
A Gambella et al.
Background: Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) have improved survival in locally advanced and metastatic esophageal, esophagogastric juncti...
RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer [0.03%]
一种机器学习打分卡（RSC4All），用于预测HR阳性/HER2阴性腋窝无转移早期乳腺癌的RSClin结果
F Jacobs,S D&#x;Amico,E Ferraro et al.
F Jacobs et al.
Background: RSClin™ combines clinicopathological (CP) and genomic data to refine predictions of distant recurrence (DR) risk and chemotherapy (CT) benefit in node-negative (N0) hormone receptor (HR)-positive/human epider...
Adverse events associated with sequential immune checkpoint inhibitor and alectinib in patients with ALK-rearranged advanced non-small-cell lung cancer [0.03%]
序贯免疫检查点抑制剂联合阿雷替尼在ALK重排型晚期非小细胞肺癌患者中不良事件的研究
J M Cheung,S Waliany,B Y Yeap et al.
J M Cheung et al.
Background: ALK tyrosine kinase inhibitors (TKIs) are the standard first-line therapy for ALK-rearranged [ALK fusion-positive (ALK+)] advanced non-small-cell lung cancer (NSCLC). In real-world practice, patients may recei...